...BioCentury it will no longer be running a Phase I trial of a COVID-19 vaccine from CanSino Biologics... ...retinoid derivative.TARGETSIFNƛ – Interferon ƛ
Veklury, remdesivir (GS-5734)
Eiger BioPharmaceuticals Inc.
Gilead Sciences Inc.
...gained RMB183.40 (87%) to RMB393.11.Following an offering that raised RMB5.2 billion, or about $750 million, CanSino Biologics... ...Tigermed Consulting Co. Ltd. (SZSE:300347; HKEX:3347), Sanyou Medical (Shanghai:688085), Schrödinger Inc. (NASDAQ:SDGR) and Sinocelltech Ltd. (Shanghai:688520).
...CanSino and China’s newer vaccine companies. Pfizer Inc. (NYSE:PFE) will exclusively promote the vaccine from CanSino Biologics... ...June, received military approval for the product (see “Readouts Raise Expectations” ).
Elizabeth S. Eaton, Staff Writer